TMZ : Innovative stratification and therapy for lung cancer management
Domain Health and wellbeing
Technology Metaomic
Challenges
Need to find new patients stratification and target
- Every 4 minutes, 10 people die from lung cancer in the world
- Poor outlook for advanced and metastatic patients (5yr survival rate <10% for advanced stages)
- Chemotherapy remains the backbone with many side effects and poor success
- Targeted therapy (EGFR, BRAF) only targets few patients and resistance comes rapidly
- Immunotherapy works well only on a small number of patients, and it is very expensive
Research team identified oxidative lung tumors, with a high mitochondrial respiration metabolism, in 50% of pulmonary adenocarcinomas.
Innovative solution
Bioenergetic precision medecine
- New stratification : oxidative (OX+) lung tumors , based on HADHA immunohistology scoring
- New target : HADHA enzyme, overexpressed in OX+ tumors
- New drug : HADHA inhibitor, reducing tumor proliferation
Competitive advantages
Unique targeted therapy based on energy metabolism
- Biomarkers for new patients stratification and aid for therapeutic orientation
- OX+ drug usable alone or in combination with current therapies
- Alternative solution for chemotherapy resistance
- Companion test for OX+ patients
Inventors
Rodrigue ROSSIGNOL, PhD
Cellular bioenergetics in human physiology and pathology
University of Bordeaux - Rare Diseases, Genetics and Metabolism (MRGM, UMR, 1211)
IP
PCT/EP2018/086278 à Claims multifunctional FAO-OXPHOS complex inhibitor for use in the treatment of high mitochondrial respiration (OX+) cancer.
Contact
Jean-Luc CHAGNAUD
%6a%6c%2e%63%68%61%67%6e%61%75%64%40%61%73%74%2d%69%6e%6e%6f%76%61%74%69%6f%6e%73%2e%63%6f%6d
